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Summary
 
Hepatitis C virus (HCV) is thought to be involved in the pathogenesis of autoimmune hepatitis
(AIH) type 2, which is defined by the presence of type I antiliver kidney microsome autoanti-
bodies directed mainly against cytochrome P450 (CYP)2D6 and by autoreactive liver infiltrat-
ing T cells. Virus-specific CD8
 
1
 
 cytotoxic T lymphocytes (CTLs) that recognize infected cells
and contribute to viral clearance and tissue injury during HCV infection could be involved in
the induction of AIH. To explore whether the antiviral cellular immunity may turn against
 
self-antigens, we characterized the primary CTL response against an HLA-A
 
*
 
0201–restricted
HCV-derived epitope, i.e., HCV core 178–187, which shows sequence homology with human
CYP2A6 and CYP2A7 8–17. To determine the relevance of these homologies for the patho-
genesis of HCV-associated AIH, we used synthetic peptides to induce primary CTL responses
in peripheral blood mononuclear cells of healthy blood donors and patients with chronic HCV
infection. We found that the naive CTL repertoire of both groups contains cross-reactive CTLs
inducible by the HCV peptide recognizing both CYP2A6 and CYP2A7 peptides as well as en-
dogenously processed CYP2A6 protein. Importantly, we failed to induce CTLs with the CYP-
derived peptides that showed a lower capacity to form stable complexes with the HLA-A2
molecule. These findings demonstrate the potential of HCV to induce autoreactive CD8
 
1
 
 CTLs
by molecular mimicry, possibly contributing to virus-associated autoimmunity.
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A
 
utoimmune hepatitis (AIH)
 
1
 
 is a chronic liver disease of
unknown etiology characterized by a persistent inflam-
matory reaction in the liver. The hallmarks of AIH are high
titers of serum autoantibodies against different autoantigens
and the presence of a hepatic, predominantly mononuclear
cell infiltrate associated with liver cell damage. Several reports
have shown the presence of autoreactive T cells in AIH pa-
tients. CD4
 
1
 
 or CD8
 
1
 
 liver-infiltrating T cells proliferate
in response to autologous hepatocytes and some of them
express high cytolytic activity (1). Peripheral T cell clones
from AIH patients also proliferate in response to liver-specific
lipoprotein and the asialoglycoprotein receptor (2). Type 2
AIH is defined by the presence of type I antiliver kidney
microsome antibodies (LKM-1) recognizing cytochrome
P450 (CYP)2D6 (3). In the liver and blood of patients with
AIH type 2, CD4
 
1
 
 and CD8
 
1
 
 autoreactive T cells recog-
nizing CYP2D6 have been detected, indicating a role of T
cells in the pathogenesis of this disease (4, 5). AIH type 2
appears to be epidemiologically linked to hepatitis C virus
(HCV) infection. Some patients with AIH type 2 have
been shown to be positive for anti-HCV antibodies (6) and
also for HCV RNA (7), suggesting that HCV may cause a
secondary autoimmune response. MHC class I–restricted
CD8
 
1
 
 CTLs are a major defense mechanism in viral infec-
tions. It has been suggested that the CTL response may
 
This work was presented in part at the 5th International Meeting on
Hepatitis C Virus and Related Viruses in Venice, Italy, June 25–28, 1998.
 
1
 
Abbreviations used in this paper:
 
 AIH, autoimmune hepatitis; APL, altered
peptide ligand; CYP, cytochrome P450; HCV, hepatitis C virus; LKM-1,
type I antiliver kidney microsome antibodies; MF, mean fluorescence;
PBA1%, PBS containing 1% BSA. 
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contribute to viral clearance as well as to liver cell injury
during HCV infection and might therefore play a role in
the induction of autoreactive antibodies and CD4
 
1
 
 helper
T cells. CTLs recognize endogenously processed antigenic
peptides in combination with MHC class I molecules pre-
sented on the cell surface. Several HCV-derived immuno-
genic CTL epitopes have been described thus far (8–13).
Amino acid sequence comparison of HLA-A2–restricted
HCV-derived CTL epitopes revealed the presence of two
human CYP sequences related to HCV core 178–187, i.e.,
CYP2A6 8–17 and CYP2A7 8–17 (Table I). Compared with
the HCV core 178 epitope, they display an eight amino
acid sequence identity, one conservative substitution at the
NH
 
2
 
-terminal anchor position (Leu to Val), and one non-
conservative substitution at position 6 (Ser to Val or Ser to
Ala). Both CYP sequences still contain the HLA-A2 bind-
ing motif, because both Leu and Val can serve as anchor
residues (14, 15). Therefore, the HCV core 178 peptide is a
candidate for molecular mimicry, that is, similarity of infec-
tious agents with host antigens. Such similarity may lead to
an inability of the host immune system to recognize the
foreign antigen or it may lead to an autoreactive immune
response at the level of antibodies or T cells (16–18).
Molecular mimicry at the level of CD4
 
1
 
 T cells seems to
play a role in several human autoimmune diseases such as
multiple sclerosis, rheumatoid arthritis, myocarditis, and her-
pes stromal keratitis (19–23). A report describing a possible
molecular mimicry at the level of CD8
 
1
 
 T cells has also
been published (24).
To determine the relevance of the sequence similarities
between an HCV-derived CTL epitope and members of
the CYP family for pathogenesis of HCV-associated auto-
immune hepatitis, we analyzed the primary CTL repertoire,
inducing primary CTL responses in the PBMCs of HCV-
negative, healthy blood donors as well as those of patients
with chronic HCV infection without markers for AIH. For
induction, we used the HCV core 178 epitope as well as
both CYP-derived peptides. CTL were then tested for their
ability to recognize all three different peptide ligands.
 
Materials and Methods
 
Study Population.
 
12 HLA-A2–positive healthy individuals
and 10 HLA-A2–positive patients with chronic hepatitis C were
 
studied. Samples of patients with chronic HCV infection were
obtained at least 6 mo after diagnosis of HCV infection. All pa-
tients repeatedly tested positive for anti-HCV antibodies, and with
one exception HCV RNA was detected by PCR. Most (8 out of
10) of the patients had not been treated with IFN-
 
a
 
 before sam-
ple collection, and the other two patients finished an ineffective
IFN-
 
a
 
 treatment before sample collection. None of the HCV
patients tested positive for autoimmune hepatitis serum markers.
Patients and healthy blood donors were negative for antibodies to
HIV and HBV and healthy donors were also negative for anti-HCV
antibodies.
 
Cell Lines.
 
The EBV-transformed B cell line JY (HLA-A
 
*
 
0201,
-B7, -Cw7, -DR4, -Drw6, and -Dpw2) and K562 cells were
cultured in RPMI 1640 medium supplemented with 
 
l
 
-glutamine
(2 mM), penicillin (50 U/ml), streptomycin (50 
 
m
 
g/ml), and Hepes
(5 mM) containing 10% (vol/vol) heat-inactivated FCS (FCS-
medium). The human B lymphoblastoid cell line AHH-1 TK
 
1/2
 
derived from the RPMI 1788 cell line (HLA type: A2, Aw33,
B7, B14) was maintained in FCS-medium. H2A3 and h2D6 cells
(AHH-1 TK
 
1/2
 
 cells transfected with vectors coding for human
CYP2A6 and CYP2D6, respectively; reference 25) were cultured
in selective RPMI 1640 medium with 2 mM 
 
l
 
-histidinol with-
out 
 
l
 
-histidine (Gentest Corp.) supplemented with 
 
l
 
-glutamine
(2 mM), penicillin (50 U/ml), streptomycin (50 
 
m
 
g/ml), and
Hepes (5 mM) containing 10% (vol/vol) heat-inactivated FCS
(h2-medium). AHH-1 T/K
 
1/2
 
, h2A3, and h2D6 cells were a gift
from Charles L. Crespi (Gentest Corp., Woburn, MA).
 
Induction of Primary CTLs.
 
PBMCs from HLA-A2–positive
healthy donors and HCV patients were isolated on Ficoll-Paque
density gradients and washed three times in PBS containing 10%
FCS-medium. 4 
 
3
 
 10
 
6
 
 PBMCs were incubated with synthetic
peptide (10 
 
m
 
g/ml; Chiron Mimotopes) in RPMI 1640 medium
supplemented with 
 
l
 
-glutamine (2 mM), penicillin (50 U/ml),
streptomycin (50 
 
m
 
g/ml), and Hepes (5 mM) containing 10%
(vol/vol) heat-inactivated human AB serum (AB-medium) for 1 h,
washed once in PBS containing 10% FCS-medium, and then
plated in 24-well plates at 4 
 
3
 
 10
 
6
 
 cells/well in AB-medium. On
day 3 and weekly thereafter, 1 ml of complete medium supple-
mented with rIL-2 (20 U/ml; EuroCetus B.V.) was added to
each well. On day 7 and weekly thereafter, the cultures were re-
stimulated with 10
 
6
 
 peptide-pulsed, irradiated (7,400 rads) autol-
ogous feeder cells in 1 ml of AB-medium containing rIL-2 (20
U/ml). The cultured PBMCs were tested for CTL activity
against different peptides on day 35.
 
Generation of Peptide-specific Cell Lines.
 
Peptide-specific induction
cultures were depleted of CD4
 
1
 
 cells using negative selection ac-
cording to the manufacturer’s instructions (Dynabeads
 
®
 
; DYNAL
A.S.) and plated at 100 cells per well in 96-well plates. Cells were
plated in FCS-medium in the presence of PHA (1 
 
m
 
g/ml), rIL-2
(30 U/ml), irradiated (10,400 rads) allogeneic PBMCs (10
 
6
 
 cells/
ml), and irradiated (22,000 rads), peptide-pulsed (10 
 
m
 
g/ml; 1 h)
JY EBV-B cells (10
 
5
 
 cells/ml). Peptide-specific wells were ex-
panded by restimulation in a 24-well plate as described above.
 
Cytotoxicity Assay.
 
JY target cells were incubated with syn-
thetic peptides (10 
 
m
 
g/ml) in FCS-medium overnight. Target
cells (peptide-pulsed JY cells or AHH-1 TK
 
1/2
 
-derived cells)
were labeled with 100 
 
m
 
Ci of Na
 
2
 
[
 
51
 
Cr]O
 
4
 
 (Amersham Pharma-
cia Biotech) for 1 h and washed four times with PBS containing
10% FCS-medium. Cytolytic activity was determined in a stan-
dard 4-h 
 
51
 
Cr-release assay using U-bottomed 96-well plates
containing 2,500 targets per well. Where indicated in the figure
legends, 2,500 K562 cells per well were added to reduce unspe-
cific lysis. Percentage of cytotoxicity was determined from the
 
Table I.
 
HCV Core 178–187 and Related Human Cytochrome 
P450 Amino Acid Sequences
 
Origin Residues Sequence
 
*
 
HCV-1 core 178–187 LLALLSCLTV
Cytochrome P450 2A6 8–17
 
?
 
V
 
???
 
V
 
????
 
Cytochrome P450 2A7 8–17
 
?
 
V
 
???
 
A
 
????
 
*
 
Amino acid sequence comparison was performed using the SwissProt
data base and identified two related human cytochrome P450 se-
quences. Identical amino acids are shown as dots. 
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formula: 100 
 
3
 
 [(experimental release 
 
2
 
 spontaneous release)/
(maximum release 
 
2
 
 spontaneous release)]. Maximum release
was determined by lysis of targets with HCl. Spontaneous release
was 
 
,
 
25% of maximal release in all assays. Specific lysis was calcu-
lated as difference between lysis of targets with peptide (or plasmid)
and targets without peptide (or plasmid).
In peptide titration experiments, JY target cells were incubated
with various peptide concentrations for 90 min after 
 
51
 
Cr label-
ing, washed once with PBS, and used as described above. In
functional MHC binding assays, JY target cells were pulsed with
synthetic peptide for 90 min at indicated times before the assay,
then washed twice with PBS containing 10% FCS-medium, in-
cubated in FCS-medium until 
 
51
 
Cr labeling, and used as described
above. CD8 dependency of target recognition was tested by ad-
dition of 10 
 
m
 
g/ml anti-CD8 antibody OKT8 (Ortho Diagnostic
Systems Inc.) during the cytotoxicity assay.
 
Peptide “Stripping” by Mild Acid Treatment.
 
JY cells were washed
twice with PBS and then put on ice for 5 min. 10
 
7
 
 cells were
then treated for 90 s with 2 ml ice-cold citric acid–Na
 
2
 
HPO
 
4
 
buffer (a mixture of an equal volume of 0.263 M citric acid and
0.123 M Na
 
2
 
HPO
 
4
 
), pH 3.2. Immediately thereafter, the eluted
cells were buffered with cold IMDM, washed with IMDM, and
resuspended at 5 
 
3
 
 10
 
5
 
 cells in IMDM with 1 
 
m
 
g/ml 
 
b
 
2
 
-micro-
globulin (Sigma Chemical Co.).
 
Competition-based MHC Class I Peptide Binding Assay.
 
Peptides
were tested for their binding affinity using the previously de-
scribed peptide binding assay (26). In brief, cells were stripped
(see above) and resuspended at 7 
 
3
 
 10
 
5
 
 cells/ml in IMDM plus
1.5 
 
m
 
g/ml 
 
b
 
2
 
-microglobulin. A fluorescein (FL)-labeled refer-
ence peptide (FLPSDC(FL) FPSV), 25 
 
m
 
l (end concentration,
150 nM), was incubated with 25 
 
m
 
l of competitor peptide (different
end concentrations) in a 96-well V-bottomed plate. 100 
 
m
 
l of mild
acid-treated JY cells was added to these wells. The mixture was in-
cubated for 24 h at 4
 
8
 
C, washed twice with PBS containing 1%
BSA (PBA1%), resuspended in PBA1% containing 0.5% paraform-
aldehyde, and analyzed by FACScan
 
®
 
 (Becton Dickinson).
The mean fluorescence (MF) value obtained in the wells with-
out competitor peptide was regarded as maximal binding and
equated to 0% inhibition; the MF obtained from the wells with-
out reference peptide was equated to 100% inhibition. Percent-
age of inhibition of binding was calculated using the formula: [1 
 
2
 
(MF 150 nM reference and competitor peptide 
 
2
 
 MF no reference
peptide) / (MF 150 nM reference peptide 
 
2
 
 MF no reference
peptide)] 
 
3
 
 100%.
 
Measurement of MHC–Peptide Complex Stability.
 
JY cells at a
concentration of 1–2 
 
3
 
 10
 
6
 
 cells/ml were incubated with 10
 
2
 
4
 
M emetine (Sigma Chemical Co.) for 1 h at 37
 
8
 
C to stop protein
synthesis and the subsequent emergence of de novo synthesized
 
class I molecules at the cell surface. Cells were washed twice with
PBS and peptide stripped (see above). 10
 
6
 
 cells were added to
200 
 
m
 
g of peptide in 1 ml and incubated for 90 min at room tem-
perature. Cells were washed twice with ice-cold IMDM and re-
suspended in 1 ml IMDM. Subsequently, the cells were incu-
bated for 0, 2, 4, and 6 h at 37
 
8
 
C and thereafter stained with
BB7.2, an HLA-A2 confirmation-specific mAb (27), and goat
anti–mouse FITC. Thereafter, the cells were fixed by resuspen-
sion in PBA1% containing 0.5% paraformaldehyde and analyzed
by FACScan
 
®
 
. The fluorescence index (FI) was calculated as FI 
 
5
 
(mean fluorescence sample 
 
2
 
 mean fluorescence background) /
mean fluorescence background without peptide. Samples were
tested in duplicate and the variation between both samples was
always 
 
,
 
10%.
Results
HLA-A2 Binding Affinity and HLA-A2–Peptide Complex
Stability. To characterize the HLA-A2 binding properties
of HCV core 178 and the homologous CYP peptides, we
determined their affinity to HLA-A2 and the stability of
the formed HLA-A2–peptide complexes. The HCV core
178 bound to HLA-A2 with intermediate affinity as previ-
ously described (28), whereas both CYP peptides bound
with low affinity (Fig. 1 A). Similar results were obtained
measuring the peptide-induced stabilization of HLA-A2
molecules at the surface of transporter-associated with anti-
gen processing–deficient T2 cells (data not shown). Deter-
mination of MHC–peptide complex stability showed that
the HCV core 178 peptide was able to form stable com-
plexes with a half-life of z5 h. The CYP2A6 8–17 as well
as the CYP2A7 8–17 peptides dissociated much faster with
half-lives of z1 h (Fig. 1 B).
Induction of Primary CTLs. To determine the effect of
the different HLA-A2 binding properties on T cell activa-
tion and antigen recognition by CTLs, we first analyzed
the naive CTL repertoire in healthy blood donors. PBMCs
from 12 healthy HCV-seronegative, HLA-A2–positive blood
donors were stimulated with synthetic HCV core 178–187,
CYP2A6 8–17, or CYP2A7 8–17 peptide in four replica
cultures. After 5 wk, the cultures were tested for CTL activ-
ity against target cells presenting each of the three peptides.
Long-term stimulation with the HCV core 178 peptide in-
duced HCV core 178–specific CTLs in nine HCV-sero-
negative blood donors (Table II). In five individuals, the
Figure 1. HLA-A2 binding af-
finities and dissociation rates of
HCV core 178–187, CYP2A6
8–17, and CYP2A7 8–17 pep-
tides. HLA-A2 binding affinities
(A) and HLA-A2–peptide com-
plex stabilities (B) of HCV core
178 (d), CYP2A6 8 (j), and
CYP2A7 8 (m) were determined
as described in Materials and
Methods. In B, the lines repre-
sent linear regression.172 Autoreactive Cytotoxic T Cells Induced by Hepatitis C Virus
HCV core 178–specific CTLs not only recognized the in-
ducing HCV peptide but also CYP2A6 and/or CYP2A7
self-peptides. A higher specific lysis of targets presenting
CYP2A7 was observed in most cases. Two donors recog-
nized all three peptides, three individuals recognized HCV
core 178 and CYP2A7 8–17, four recognized HCV core
178 only, and three did not show a CTL response after
stimulation with HCV core 178. Representative results of
three donors are shown in Fig. 2 a. These results as well as
data obtained from CTL lines derived from positive cul-
tures (data not shown) indicate the presence of three phe-
notypes of HCV core 178–specific CTLs: CTLs recogniz-
ing HCV core 178 only, CTLs cross-reactive with HCV
core 178 and CYP2A7, and CTLs specific for HCV core
178, CYP2A7, and CYP2A6. We did not find CTLs rec-
ognizing CYP2A6 without recognition of CYP2A7, nor
cells recognizing one of the CYP peptides without recog-
nition of HCV core 178. Importantly, no CTL response
could be induced with the self-peptides CYP2A6 8–17 (Fig.
2 b) and CYP2A7 8–17 (Fig. 2 c) in any of the 12 donors
tested. This fits with our observation of different MHC–pep-
tide interactions, because peptide-induced MHC stability and
immunogenicity of the peptide are strongly correlated (28).
The same strategy was used to analyze the HCV core
178–specific CTL repertoire in patients with chronic HCV
infection without markers for AIH. The percentage of pa-
tients having cross-reactive CTLs is comparable to that of
healthy donors (Table II), suggesting that the peripheral
pool of naive CTLs specific for HCV core 178 is compara-
ble to the one of uninfected individuals and that the pre-
cursor frequency of cross-reactive CTLs is similar. This is
not astonishing, as chronic HCV infection is associated
with a low number of CTLs in the peripheral blood (29, 30).
Peptide Recognition by Cross-reactive CTL Lines. HCV core
178–induced CTL lines derived from donor 2 were used to
test the biologic function of the peptides in cytotoxicity as-
says. Despite different MHC binding affinities and abilities
Table II. Phenotype Distribution of HCV Core 178–inducible 
CTLs in Healthy Donors and Patients with Chronic HCV Infection
Peptides recognized
Healthy donors*
(n 5 12)
Chronic
HCV patients*
(n 5 10)
HCV core 1 CYP2A7
1 CYP2A6 2 (17%) 2 (20%)‡
HCV core 1 CYP2A7 3 (25%) 2 (20%)
HCV core 4 (33%) 4 (40%)
None 3 (25%) 2 (20%)
*Number (percentage) of individuals recognizing the indicated pep-
tides after primary induction with HCV core 178. CTL responses of
.15% specific lysis at an E/T ratio of 40:1 in primary induction cul-
tures were considered positive.
‡One of these patients was not positive for CYP2A6 according to the
criteria mentioned above, but CYP2A6-recognizing cell lines could be
established by limiting dilution.
Figure 2. Peptide-specific cytotoxicity induced in vitro with HCV core
178–187, CYP2A6 8–17, or CYP2A7 8–17 peptides. PBMCs from healthy
HCV-seronegative blood donors were stimulated with HCV core 178–187
(a), CYP2A6 8–17 (b), or CYP2A7 8-18 (c) in four replicas (1–4). After
5 wk of stimulation, peptide-specific lysis of each culture was determined
on JY target cells pulsed with HCV core 178–187 (white bars), CYP2A6
8–17 (black bars), or CYP2A7 8–17 (gray bars). E/T cell ratios were fixed
for each culture and ranged from 20:1 to 40:1 for the different cultures.
to stabilize MHC complexes, all three peptides were recog-
nized by CTLs with the same efficiency (Fig. 3 A). The higher
off-rate of the CYP peptides had no effect on CTL recog-
nition when the peptide-pulsed target cells were further in-
cubated without peptide for up to 24 h before exposure
to CTLs (Fig. 3 B). An explanation for this phenomenon
could be the CD8 dependency of target recognition. Al-
though lysis of target cells presenting HCV core 178 is
markedly reduced by the anti-CD8 antibody OKT8, rec-
ognition of CYP2A7 is less affected and there is no effect on
recognition of CYP2A6 (Fig. 3 C). These findings were
unexpected but similar findings had been observed by
al-Ramadi et al., demonstrating that the pattern of func-
tional activities of variant peptides does not always corre-
late with MHC binding (31). In fact, other mechanisms in-
volved in the interaction between the CTL and the target
cell may be important, such as the TCR affinity for the173 Kammer et al.
MHC–peptide-complex, and CD8 binding to MHC class
I, as well as other costimulatory and cell adhesion mole-
cules (32). To assess the role of CD8 binding on CTL–target
cell interaction, we used a panel of three different anti-CD8
antibodies and tested their effect on target cell lysis. A rep-
resentative experiment is shown in Fig. 3 C using the OKT8
antibody. Although recognition of HCV core 178 depends
in part on CD8 availability, self-peptide recognition of
CYP2A6 does not. Further studies will be required to define
the mechanism responsible for the discrepancy observed be-
tween peptide–MHC binding and CTL-mediated cytotoxicity.
Recognition of Endogenously Synthesized Antigen. The abil-
ity of HCV core 178–induced CTLs to recognize endog-
enously synthesized CYP2A6 antigen was studied using the
AHH-1 TK1/2 cell line transfected with CYP2A6 (h2A3),
and cells transfected with the unrelated CYP2D6 (h2D6) as
target cells in 4- and 8-h cytotoxicity assays. Killing of
CYP2A6-transfected cells by CTL lines from donor 2 was
higher than lysis of the parental cell line AHH-1 TK1/2 or
control cells transfected with CYP2D6 (Fig. 4), suggest-
ing that naturally processed CYP2A6 8–17 peptide is gen-
erated by the proteolytic machinery and presented on the
HLA-A2 molecule.
Discussion
The HCV core 176 peptide has been described as a tar-
get epitope for CTLs that are present in the peripheral
blood of patients with chronic HCV infection (10). This
peptide is processed and presented via the endogenous
MHC class I pathway (11). We used PBMCs from healthy,
HCV-seronegative individuals as well as from patients with
chronic HCV infection to induce primary CTL responses
against this epitope and two homologous CYP-derived
peptides. CTLs induced with the HCV core 178 peptide not
only recognized the inducing HCV peptide, but also showed
autoreactivity, lysing targets presenting CYP-derived self-
peptides and target cells stably transfected with a plasmid
coding for the whole CYP2A6 protein, showing that the
CYP epitope is also presented via the endogenous MHC
class I pathway. Among the CTLs we could distinguish three
different functional types in the same individual: cells recog-
nizing HCV core 178 only, cells with cross-reaction be-
tween HCV core 178 and CYP2A7, and cells recognizing
HCV core and both CYP epitopes, indicating a polyclonal
response against HCV core 178 with a distinct hierarchy.
The induction of self-reactive CD81 CTLs by a viral
epitope is compatible with molecular mimicry (resemblance of
pathogen and host antigens), a mechanism that has been
described mainly at the level of antibodies and CD41 T
cells (16–18). Molecular mimicry at the level of T cells has
been implicated in human autoimmune diseases such as
multiple sclerosis (19, 20), rheumatoid arthritis (21), and
myocarditis (22), as well as in herpes stromal keratitis (23).
A recent study also describes cross-reactivity of CD81 T
cells specific for a myelin-derived peptide with a Saccharo-
myces cerevisiae peptide (24). In this case, cross-reactive
CTLs could only be induced with the self-peptide and not
with the Saccharomyces antigen.
In our study we could not induce CTLs with the CYP-
derived self-peptides, although the same self-peptides were rec-
Figure 3. Peptide recognition by CTL lines. Cross-reactive CTL lines derived from donor 2 were tested for their ability to lyse (A) JY target cells preincu-
bated at various concentrations of peptide and (B) JY target cells pulsed with 10 mM peptide and further incubated without peptide before exposure to CTL.
Peptides were HCV core 178–187 (d), CYP2A6 8–17 (j), and CYP2A7 8–17 (m). (C) The effect of anti-CD8 antibodies on target cell recognition was
tested by addition of OKT8 antibody (10 mg/ml) during the cytotoxicity assay. Shown are the mean 6 SD of three to four replicas at an E/T ratio of 10:1.
Figure 4. Recognition of endogenously processed cytochrome P450.
Cross-reactive CTL lines derived from donor 2 were tested for their ability to
lyse AHH-1 TK1/2 target cells transfected with CYP2A6 (circles) or
CYP2D6 (squares). Shown is the plasmid-specific lysis: lysis of transfected
cells 2 lysis of untransfected cells in a 4- (filled symbols) or 8-h (open symbols)
cytotoxicity assay. The 4-h assay was performed in the presence of K562 cells.174 Autoreactive Cytotoxic T Cells Induced by Hepatitis C Virus
ognized by CTLs induced with the HCV core 178 epitope.
This indicates different T cell activation properties of the self-
epitopes compared with the HCV peptide as described for
altered peptide ligands (APLs), which are analogues of immu-
nogenic peptides with amino acid substitutions inducing dif-
ferent effects in CTLs. APLs can act as agonists leading to full
activation of T cells, partial agonists inducing only a reduced
T cell response, or even antagonists inhibiting a response
against the unaltered immunogenic epitope (33, 34). The
molecular mechanisms of APL-induced partial T cell activa-
tion are still a matter of debate (35). Complexes of the native
ligand or APLs with MHC molecules binding to the TCR
can induce different intracellular signals in T cells (36–38), ei-
ther by different oligomerization of necessary molecules
(CD3, CD8, or other molecules), or by a failure of the APL
to induce a required conformational change in the TCR.
Other studies state that the level of T cell activation is depen-
dent on the number of TCRs triggered in a process of serial
engagement of many TCRs by a few peptide–MHC com-
plexes, allowing a single CTL to generate different biological
responses (39). Although specific cytotoxicity is already de-
tectable at very low peptide concentrations, IFN-g produc-
tion and proliferation require higher concentrations corre-
sponding to higher numbers of TCRs being triggered (40).
This is in accordance with the finding that the immunogenic-
ity of antigenic peptides strongly correlates with the stability
of MHC–peptide complexes formed (28), indicating that a
high number and a high stability of MHC–peptide complexes
is essential to trigger a sufficient number of TCRs to fully ac-
tivate naive T cells. Despite this, the final effect of affinity dif-
ferences or kinetic changes on the multimolecular interac-
tions during antigen recognition cannot be predicted, as there
is no strict correlation between functional activity of the vari-
ous peptides and their MHC binding efficiency and the affin-
ity of the MHC–peptide complexes for the TCR (31).
We have shown that the signal induced by the unstable
complexes of HLA-A2 and CYP-derived self-peptides is
not sufficient to activate naive CTLs. In the same way there
is evidence that the CYP peptides neither induce negative
selection during thymic development nor lead to anergy, as
we detected cross-reactive CTL precursors in the periph-
eral blood. On the other hand, the HCV core 178 peptide
that forms stable MHC–peptide complexes is able to in-
duce full activation including maturation of CTLs. In the
activated cross-reactive CTLs, cytolytic functions can then
be induced by the HCV peptide, and also by the CYP-
derived APLs, as cytotoxicity requires a lower threshold of
activation than proliferation. Once activated, a subpopula-
tion of cross-reactive CTLs that shows no differences in
recognition of the three peptide ligands, because they rec-
ognize the HCV core 178 and the CYP peptides at similar
peptide concentrations, can be found.
The clinical observation that HCV infection is preceding
the development of LKM-1–positive AIH is in accordance
with our hypothesis that antiviral immune response has to
predate autoimmunity (41, 42). Moreover, the presence of
autoreactive T cells in the blood and the liver of AIH type
2 patients has been demonstrated, indicating a role for both
CD41 and CD81 T cells in the pathogenesis of this disease
(4, 5). Cross-reactive CTLs may contribute to liver cell dam-
age by lysis of infected and uninfected hepatocytes during on-
going viral infection and by lysis of uninfected autoantigen-
expressing hepatocytes after viral clearance. However, the
presence of virus-inducible autoreactive CTLs alone is not
sufficient to lead to typical AIH, as none of the tested HCV
patients had markers for AIH (LKM-1 autoantibodies). Prob-
ably the presence of autoreactive CD81 as well as autoreac-
tive CD41 helper T cells is required for the induction of
AIH. LKM-1 antigen (CYP2D6)–specific CD41 T cells de-
tected in AIH patients would be needed for the activation of
B cells secreting the AIH marker LKM-1 autoantibodies.
Furthermore, autoreactive CD41 T cells could maintain the
autoreactive CD8 T cell response after viral clearance, com-
parable with chronic viral infections where CD41 T cells are
essential for maintaining the CTL response (43–46).
In summary, several arguments underscore the biological
relevance of our findings. First, the viral epitope as well as the
self-epitopes are naturally processed and presented by human
host cells. Second, the self-epitopes and the viral epitope are
coexpressed and colocalize to the liver in natural HCV infec-
tion, and expression of CYP2A6 is even enhanced in HCV-
infected livers (47). Third, the absence of CYP-inducible
CTLs in the peripheral blood suggests that central or periph-
eral tolerance mechanisms are operational, indicating that the
self-epitopes are presented to T cells in vivo. Fourth, the data
presented show a high level of cross-recognition of virally in-
duced CTLs against the self-peptides, suggesting that they can
mediate liver cell damage to uninfected cells. Fifth, another
line of evidence links HCV infection to autoimmune hepati-
tis type 2 (6). This disease has been described to occur subse-
quent to HCV infection (42) and, interestingly, in association
with HLA-A2 (48). Typically, it is associated with the pres-
ence of autoantibodies directed against cytochrome P450
2D6 (3, 6), as well as autoreactive CYP2D6-specific T cells,
suggesting the parallel occurrence of autoreactivity against cy-
tochrome P450 at the level of B and T cells (4, 5). It can be
hypothesized that liver cell damage mediated by virus-specific
CTLs leads to the release of intracellular proteins like
CYP2D6, uptake of these autoantigens by professional APCs,
and autoantibody formation in the presence of autoreactive
CD41 T and B cells. After viral clearance, the autoimmune
disease is upheld by ongoing hepatocyte lysis by cross-reac-
tive, HCV-induced CTLs maintained by autoreactive helper
T cells. The coincidence of HCV, autoreactive B cells, and
autoreactive CD81 and CD41 T cells is thus required for the
induction of HCV-associated AIH. This would explain the
relatively low frequency of AIH among HCV patients despite
the high number of individuals with cross-reactive CTLs.
Our findings demonstrate the potential of HCV to in-
duce autoreactive CD81 CTLs by a molecular mimicry of
CYP2A6/2A7 by the core protein and therefore show a
possible mechanism by which HCV may trigger AIH. Fur-
ther studies analyzing the cross-reactivity pattern of HCV
core–specific CTLs derived from untreated patients with
active HCV-associated autoimmune hepatitis are required
in order to establish this mechanism.175 Kammer et al.
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